# Tobramycin 300 mg Once-a-day (o.d.) Aerosol in Adults With Cystic Fibrosis

> **NCT01608555** · PHASE4 · COMPLETED · sponsor: **University of Milan** · enrollment: 10 (estimated)

## Conditions studied

- Cystic Fibrosis

## Interventions

- **DRUG:** tobramycin

## Key facts

- **NCT ID:** NCT01608555
- **Lead sponsor:** University of Milan
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2012-01
- **Primary completion:** 2012-07
- **Final completion:** 2012-07
- **Target enrollment:** 10 (ESTIMATED)
- **Last updated:** 2012-07-24

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01608555

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01608555, "Tobramycin 300 mg Once-a-day (o.d.) Aerosol in Adults With Cystic Fibrosis". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT01608555. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*